CURRICULUM VITAE
12 January 2022

Chwen-Cheng (Nathan) CHEN, MD, PhD, MSc, MBA

228 Laurelglen Ct. Danville, CA 94506, USA
+1 925-263-2547 or +1 860-326-8018 (US)

12F, #391, Sec 4 Hsing-Yi Road, 110 Taipei, Taiwan
+886 (0)916-184-701 (Taiwan)

123456789nc@gmail.com

CURRENT EMPLOYMENT:

1. Chief Medical Officer, Adimmune Corporation
2. **Visiting Professor**, Institute of Biotechnology & Pharmaceutical Research, NHRI

EDUCATION:

MD in Medicine, 1984
China Medical College, Taiwan

PhD in Psychiatry and Social Medicine, 1994
King's College London & Institute of Psychiatry,
University of London, United Kingdom

MBA in International Business Administration & Management, 2007
University of South Australia, Australia

MSc in Pharmaceutical Medicine, 2007
Hibernia College, Ireland

EXPERIENCE IN MANAGEMENT

Industry

1. Chief Medical Officer in biotech companies specialized in biologics. Accountable and oversee company pipeline development strategy and plans.
2. Clinical Group Head, China – 5 direct report Clinical Program Leads and a team of total 12 clinicians. Accountable and coordinating teams on registration and market entry strategy and development plan for Pfizer global product profiles into China market, including budgeting, resource allocation, product development timeline etc.
3. Medical Office management (Country Medical Director), including medical affairs, clinical research & operation, regulatory affairs, outcome research and safety management – 8 direct reports
4. Country marketing management (CNS Marketing Director)– 3 direct reports
5. US Regional, Clinical/Medical – 1 direct report
6. Oversee global regulatory and clinical development strategy
7. Asia Clinical Development Head – 6 direct reports
8. Independent Member, Board of Director of a Listing Company
9. Founder of a Biopharmaceutical consulting firm

Academia

1. Chair of an Academic and Clinical Department in a National Medical School
2. Chair, National Joined IRB, Taiwan
3. Secretary General, IRB at National Cheng Kung University, Taiwan

EXPERIENCE & SKILLS IN DRUG DEVELOPMENT

1. Corporate Pipeline portfolio management and planning, including compound searching and licensing in evaluation
2. Development and implementation of clinical development strategy and plan, New Drugs and Medical Devices
3. Regulatory interaction experiences: US, EU/MHRA, TGA, TFDA, KFDA, CFDA, Indonesia Agency
4. Submission experiences
    a. PF 04360365 (Anti-Abeta monoclonal antibody) Alzheimer's Disease program US FDA End of Phase 2 (EOP2) briefing document preparation & face to face meeting
    b. European Pediatric Investigation Plan (PIP) of pregabalin in Anxiety Disorders
    c. PD 0332334 EOP2 briefing document preparation in Generalized Anxiety Disorder
    d. NDA in US for Lyrica monotherapy & adjunctive therapy in GAD
    e. 9 NDAs approval in Taiwan
    f. IND OBI-833-001 Phase I in Breast, Lung, Gastric and Colorectal Cancer
    g. NDA for enterovirus vaccine
5. Knowledge, understanding and hands-on experiences in Drug Development, especially pre-POC and Post-POC clinical development programs.
6. Clinical Program Lead in Phase II-III development in biologic and small molecule compound
7. Project clinical lead in multinational Phase III pivotal trials, including US, EU and Asia sites
8. Phase II-III pivotal trial design, initiation, conduction, monitoring and close out
9. Applying concept of Quality by Design (QbD) to develop Integrated Quality Management Plan (IQMP) for Phase III pivotal clinical trial design and conduction (a Pilot initiative with US FDA)
10. Integrate safety monitoring at program level, including establishing DSMB (or DMC) and project safety review plan
11. Medical Monitoring in Phase I – III trials, especially in Oncology, CNS, Hemophilia, and Inflammatory Diseases
12. Phase I Human Abuse Liability protocol design
13. Phase I Drug-Drug Interaction protocol design and conduction
14. Phase I Drug Cognitive Function Effect study protocol design
15. Program Development for new indication, eg PD 0332334 and pregablin in Social Anxiety Disorder

16. Project clinical lead in multinational Phase IV post-approval commitment trials requested by FDA or EMA
17. Methodology study: validation of Placebo Response Screening Scale (PRSS), changes in Sexual Functioning Questionnaire (CSFQ), and Measurements in Human Abuse Liability
18. Safety Study: Ophthalmology Safety, Drug withdrawal
19. Disease Area: Oncology, Generalized Anxiety Disorder, Social Anxiety Disorder, Major Depression, Schizophrenia, Bipolar Disorder, Epilepsy, Alzheimer's Disease, Hemophilia, Pain & inflammation, Osteoarthritis, Hyperlipidemia, Osteoporosis, Therapeutic Vaccine in Oncology, Anemia associated with chronic kidney disease, and preventive vaccine
20. Country Medical Office management, including clinical research & operation, regulatory affairs, medical affairs and safety management
21. Asia Clinical Development Strategy and Management
22. Global and Country level Clinical Research Strategy and Management
23. Bridging strategy and issue in Asia
24. Vaccine pipelines and product development against SARS-CoV-2 infection, EV71, JEV and others

EXPERIENCES IN CONSULTING SERVICES (not limited to)

Business Management Strategy and Decision

- Help management and project teams to make critical business decisions, including development target selection, milestone advancement (such as Phase II to Phase III GO/No Go), strategic decision on clinical trial design in accordance with development (clinical, medical, & regulatory) and commercial strategy, and etc.
- Portfolio/compound development target selection and management, development plan & risk management, and commercialization risk assessment
- Asset value evaluation for licensing, including valuation, deal strategy and proposal, competition landscape evaluation, and market potential evaluation.
- Management & Scientific Advisor to provide advisory consultancy on corporate general management, business development strategy and strategic decisions on pipeline/ program development strategy and plan
- Registration and market entry strategy to ASEAN and SE region countries
- Sit in Board of Director as independent director of a listing company

Clinical Development & Regulatory Affairs

- Lead and drive product development strategy, clinical trial design and implementation oversight as independent consultant working with and training client's in-house team.
- Providing advisory consultancy to project team on global registration trials management, including strategy of global placement, CRO selection and collaboration construct, oversight structure and processes over global clinical trial implementation, filling strategy, and other related details of trial operational management
- Providing consultation on statistical strategy and oversight over client's data management, analyses and interpretation
- Directing and managing clinical trial implementation, especially over medical/clinical oversight on behalf of client
- Design for client phase III pivotal international trial program for NDA/BLA purpose
- IND, EOP2, NDA/BLA submission strategy, planning and implementation

Others

- Advisory consultancy on translational research, especially on biomarker development strategy, plan and validation
- Helping client to solve regulatory issues and meeting with local or global regulatory agencies
- Assist or conducting due diligence on behalf of clients

EXPERIENCE & SKILLS IN MEDICAL AFFAIRS

1. Country Medical Director, development and executing country medical team vision and strategy aligned with Global, Regional and Country business objective
2. Regulatory strategy and plans oversight
3. Field based medical communication (at Asia regional level)
4. Key Opinion Leader development strategy
5. Establishing medical information function at country level
6. Building and Leading medical affair group at Country Level
7. Review and approval of medical information and detailing material for use in the market place
8. Co-chair of publication committee in a drug development program for general anxiety disorder

EMPLOYMENT HISTORY:

Chief Medical Officer, 1 January 2021 - Present

- Accountable for pipeline product development strategy and plan
- Oversee development plans implementation
- Accountable global regulatory strategy and oversee activities related to regulatory affairs
- Oversee medical affairs activity, including pharmacovigilance
- Supporting corporate development strategy and plan from medical/clinical/regulatory perspective
- Supporting asset evaluation for licensing and co-development projects

Founder, JN Biopharma Consulting, September 2016 - Present

JN Biopharma Consulting provides consultancy services on every aspect of drug/device development and commercialization at strategy or technical level, across all phase of drug/device development value chain. JN has a virtual team comprising of different key expertise to provide services according to client's need.

Currently having active consultancy contract with 7 biopharmaceutical companies, 2 medical device companies and 2 academic institutions with capacity in new drug development.

Advisory consultancy services include (not limited to)

- Portfolio/compound development target selection and management
- Business development strategy
- Clinical development strategy, planning, decision and implementation
- Regulatory strategy and interaction with regulatory agency
- Biologics or Chemical Drug Development across Therapeutic Areas
- Biopharmaceuticals or Devices Development
- Asset evaluation, development plan & risk management, commercialization risk assessment
- Enhanced Clinical Trial Design (ECTD) & Enhanced Quantitative Drug Development (EQDD)
- Trial design and implementation planning for all phases
- Medical monitoring & Pharmacovigilance planning and management
- Statistical strategy, design, analyses & interpretation for product development
- Drug Safety Management Board (DSMB) or Independent Committee for Data Monitoring (ICDM) in Clinical trial
- Strategy, Design and Management for Interim Analysis for Clinical Trial
- Pre-clinical enabling studies and plan
- Translation studies
- Biomarker development and validation
- Management Advisory Board or Scientific Advisory Board

Activities involved with current clients

- Consulting contract with 7 Biopharmaceutical Companies, 2 Medical Device Companies and 2

Academic Institutions with capacity in new drug development

- Driving product development strategy, clinical trial design and implementation oversight as Independent Consultant working with and training client's in-house team.
- Sitting in Management & Scientific Advisory Board to provide Advisory Consultancy to management team on corporate general management, business development strategy and strategic decisions on pipeline program development strategy and plan
- Providing advisory consultancy to project team on global registration trials management, including strategy of global placement, CRO selection and collaboration construct, oversight structure and processes over global clinical trial implementation, filling strategy, and other related details of trial operational management
- Helping client's team (both management and project teams) making critical business decisions, including Development Target Selection, Milestone Advancement (such as Phase II to Phase III GO/No Go), Strategic Decision on clinical trial design in accordance with development (clinical, medical, & regulatory) and commercial strategy, and etc
- Conducting licensing in products evaluation including valuation, deal strategy and proposal, Competition landscape evaluation, and market potential evaluation.
- Assist or conducting due diligence on behalf of clients
- Providing consultation on statistical strategy and oversight over client's data management, analyses and interpretation
- Advisory consultancy on translation research, especially on biomarker development strategy, plan and validation
- Directing and managing clinical trial implementation, especially over medical/clinical oversight
- Solving regulatory issues and meeting with regulatory agencies.
- Sitting in Board of Director as Independent Member of a listing company

Visiting Professor, Institute of Biotechnology & Pharmaceutical Research
National Health Research Institute **June 2017 - Present**

- Advisory input to each new drug development project team of IBPR on development strategy and development plan.
- Medical/clinical oversight over projects in clinical development phase

VP, Chief Medical Officer & Head of Global Medicine Development
OBI Pharma Inc, **Jan 2015 – August 2016**

Join OBI Pharma from Jan. 1, 2015 reported to CEO, as Vice President, Chief Medical Officer (CMO), and Head of Global Medicines Development.

As the CMO, I serve as a key member of the executive team. I am responsible for developing the company's global product portfolio strategy to bring products to market in compliance with global regulatory, legislative and medical/health requirements. I chair OBI Development Strategy Team Meeting to coordinate teams of R&D, Translation Medicine, Clinical Development, Regulatory Affairs, and Commercial Development to ensure alignment and a seamless transition from the R&D to Commercial phases of development of OBI's global pipeline. My position has functional responsibility for all stage clinical development activities which starts from First in Human, proof of concept, Phase III pivotal through Phase 4 programs including on-market products. I am also responsible for developing strategic plans for the company's late stage product portfolio to ensure development programs meet quality and safety standards required by medical and regulatory agencies. I have responsibility for all late stage clinical development, including providing leadership to medical affairs, pharmacovigilance, pharmacoeconomics, to ensure a successful product approval and launch. I oversee the portfolio management activities for the company to ensure appropriate objectives and resources are deployed to meet strategic portfolio plans delivering on key milestones to advance all of the company's products in development. I am responsible for representing the company with regulatory and legislative agencies, globally addressing the scientific and medical/health aspects of the company's product portfolio; may also provide consultative guidance on health-related matters to leaders across the company and with outside health/medical and regulatory organizations. I oversee the company's

product portfolio investments to meet fiscal year goals providing strategic input to the annual and long-range budgetary process.

As VP, Head of Global Medicine Development of OBI, I am responsible for clinical development strategies including Phase 1 through 3, lifecycle management, medical affairs, safety responsibilities, scientific interactions with regulatory bodies, and interactions with corporate partner(s); supervise and direct the activities of other Clinical Research staff including Biostatistics, Data Management, Clinical Operations, Regulatory, Quality and Medical Affairs; lead and oversee the strategic and tactical development of clinical trials programs, including protocol writing, interpretation of clinical data, and literature reviews; and ensures the consistent application of state-of-the-art scientific and ethical methods to design clinical investigational trials of the highest quality. OBI is a Biotech company focusing on development of therapeutic vaccine or monoclonal antibody in oncology.

Pfizer Global Innovative Pharmaceutical Business (GIPB) Jan 2014 – Oct 2014
Pfizer Emerging Market & Established Product Business Unit Jan 2013 – Dec 2013

Asia Clinical Development Head, Development, MDG, EMBU Jan 2013 – Dec 2013
Clinical Group Head, Global Medicines Development, GIPB Jan 2014 - Oct 2014

In January 2013, I took the role as Head of Clinical Development, Asia, reported to the VP, Development, EMEP business unit. In this role, I started from assisting VP to design and to propose a strategic plan for establishment of a China-based EM clinical team, including scope of responsibility, organization relationship, FTE and budgetary resource requirement. The China-based EM clinical team in planning would be responsible for design, conduction, monitoring and reporting of clinical trials for China/Asia registration purpose.

After the team was established in July of 2013, I led the team and served as the key interface on Development Assets for China/Asia and provided coordination between various functional lines and platforms in Asia, with a primary focus on China. I also managed and coached this group of Clinical Scientists working as the primary study clinicians of clinical trials for China/Asia registration across Disease and Therapeutic Areas in support of Emerging Market Business Unit objectives in China/Asia and providing the group resource for their technical training and career development.

In 1st January 2014, along with organization restructure, my team was expanded and mapped into the Global Clinical Sciences group in the newly established Global Innovative Pharmaceutical Business (GIPB). My title of role became the Clincial Head, China, administratively reporting to the VP of Global Clinical Strategy & Support (GCSS), Global Medicines Development of GIPB. Functionally, I lead a group of Clinical Program Leads/Clinicians within Pfizer Global Medicines Development organization responsible for development and implementation of clinical development strategy and plan of Pfizer products across all therapeutic and diseases areas leading to registration approval in China. In this role I serve as the overarching interface on Pfizer Development Assets (both early & late phase) in China to ensure coordination between various functional lines and platforms in China as well as collaboration between global development teams to support Pfizer business objectives in China. Responsibility includes 1) Oversee and lead to collaborate with global clinical and local commercial development collegues for Pfizer China Portfolio evaluation and planning; 2) Oversee and lead to set up China portfolio development strategy and clinical plans to support registration approval in China; 3) Oversee to ensure timely and quality development and implementation of clinical development strategies that will deliver significant portion of clinical plans leading to approval in China; 4) Be accountable for overall clinical deliverables of Pfizer portfolio in China; and 5) Manage, coach and provide resource for technical training and career development of my group members.

At the same time I continuously sitting on (Neuropsychiatric and Abuse Potential Advisory Council (NAPAC) to provide professional input to development teams on abuse liability and suicidality assessment

Pfizer Primary Care Business Unit January 2009 to November 2012

Senior Director, Clinical Sciences, MDG September 2011 to November 2012

Regional Clinical Development Director (RCDD), US West Coast (13 States), North America Regional Medical Monitoring (RMM) Organization. RMM is a medically qualified individual embedded within a local/regional clinical operations group acting as a local extension of a business unit's clinical group and providing local medical oversight of a clinical study. Responsible and accountable for providing day-to-day medical oversight of clinical development performed in their region including input to development plan/study designs and ensuring optimal site/patient selection, patient safety, scientific integrity, site compliance with protocol and ICH-GCP requirements & investigator/KOL interaction during study execution. Each RMM is responsible for several different studies, across therapeutic and disease areas and business units (BUs).

As RCDD, I am leading a team to look after activities mentioned above in 13 States of the US West Coast to ensure 1) Medical and safety oversight at the investigational site level in high risk clinical trials; 2) Assuring subject's safety is well assessed and managed at the site level; 3) Ensuring and enhancing quality and integrity of clinical trial conduction; 4) Ensure protocol compliance, in particular prevention and management of deviations with safety concerns; 5) Ensures excellence in medical & safety oversight at site level through education, training, mentorship and performance management of each RMM on the team.

In this role, I am assigned as Global RMM Study Lead of five Pfizer high risk studies to coordinate global RMM team providing support in medical oversight to study clinical team at Region/Country and site level.

Therapeutic/disease areas covered are Oncology, Alzheimer's Disease, Hemophilia, and Autoimmune Inflammatory Bowel Disease.

Sitting on Neuropsychiatric and Abuse Potential Advisory Council (NAPAC) to provide professional input to development teams on abuse liability and suicidality assessment and as Liaison of NAPAC to Emerging Market Business Unit in Suicidality Assessment.

Director, Clinical Sciences, MDG **March 2010 – August 2011**

Clinical Program Lead in a full development team (Phase Ib/III) of a monoclonal antibody in modifying disease progression course of Alzheimer's disease. Responsibilities include 1) Responsible for design, execution, monitoring and reporting of clinical programs; 2) Chairing clinical subteam to drive and ensure scientific and technical excellence in the team; 3) Overseeing in clinical trial safety review and analysis and tracking of emerging efficacy and safety profile; 4) Supervising medical monitor to ensure adherence to Safety Review Plan to perform and document regular review of individual subject safety data and cumulative safety data with SRML; 5) Accountable for development of Clinical Development Plan; 6) Assist GCL in discussion with regulators and with the resolution of queries from drug regulatory agencies and lead or contribute to writing and reviewing responses to regulatory queries; 7) Responsible for development of clinical documents, including protocol, clinical study reports, clinical components of regulatory submissions; 8) Coordinate functional teams and representatives in the development for assigned projects, such as biomarkers selection and qualification plan, abuse liability strategy and plan, suicidality assessment strategy and plan, product concept, IB update, Skin Rash Monitoring Plan; DSMB plan; Renal Safety Monitoring Plan, etc.

Sits on (Neuropsychiatric and Abuse Potential Advisory Council (NAPAC) to provide professional input to development teams on abuse liability and suicidality assessment and as Liaison of NAPAC to Emerging Market Business Unit in Suicidality Assessment.

Director, Clinical Sciences, MDG **January 2009 – September 2009**

Reports to Clinical Program Lead of Lyrica in psychiatric therapeutic area. Responsibilities include lead clinician of two phase IV post-approval commitment clinical trials (Discontinuation and ophthalmology safety trials) to the FDA and EMEA. Sits on Lyrical Disease Area Team (LDAT) in psychiatry & epilepsy to contribute Lyrical business strategy in psychiatric and epilepsy Franchises from clinical perspective.

Continue sitting in NAPAC to provide professional input to development team on abuse liability and suicidality assessment.

Pfizer Global Research & Development June 2007 – December 2008

Associate Director, Neurosciences Clinical Development June 2007 – December 2008

Reports to Global Clinical Lead of a Phase III program, working as a specialized clinician-scientist on the phase 3 drug development projects, where I am responsible for the design, implementation, conduct, and summarization, interpreting, and reporting of studies in generalized anxiety disorder, including studies of the efficacy and safety of this new chemical entity. The work is with a matrix team of clinical colleagues (other clinicians, statisticians and clinical pharmacologists) and involves contributing to the clinical development plan, and providing medical and specialized psychiatric support during clinical trial conduct.

Assignment includes lead clinician of two pivotal phase III trials and lead clinician of phase I ADME study, drug-drug-interactions studies (4 studies), PK in renal impairment and hemodialysis patients (2 studies), abuse liability study and cognitive/psychomotor effect study of the compound. In addition, my responsibility also includes leading a small team for the development plan in Social Anxiety Disorder for the same compound, representing Clinical team as Co-chair of publication committee driving publication strategy and plan of the compound, establishing and driving abuse liability strategy and plan implementation. As the lead clinician in each clinical trial, I am responsible for design and protocol development of each trial. In collaboration with a clinical operation team, I also involve in country and site selection, medical monitoring, and oversight trial conduction, including initiation and enrollment. The development team won 2008 Clinical Development Team Award.

During this period, I was also assigned to be Co-chair of Publication Subcommittee to drive product publication plan and execution.

I am also sitting on the Corporate Safety Council, Neuropsychiatric & Abuse Potential Advisory Council (NAPAC) to provide professional input to each development team on abuse potential and suicidal risk evaluation,

Pfizer Taiwan, Japan/Asia, Pfizer Global Pharmaceuticals November 2004 – June 2007

Medical Director November 2004 – June 2007

Report to Taiwan Country General Manager and Asia Pacific Regional Medical Director. Responsible for management of the medical division operations at country level, including medical administration, clinical research, regulatory affairs, safety & risk management, medical marketing, medical information, outcome research and quality standard and training. Eight direct report managers and 37 staffs.

Major achievements include: 1) Implement RegMax Taiwan project, with support from regional and HQ, to expedite product registration process to maximize Pfizer's new product value (estimated potential incremental sales was US$142M in 10 years by shortening approval timeline); 2) From 2004 onward, completed 9 NDA submissions, nine products had been approved; 3). Establish Taiwan clinical research capacity to actively participate and contribute Pfizer global development plans as well as support local business needs. Achievements include a) Completed 3 Phase IIIb local registration trials (valdecoxib, varenicline, and pregabaline). I actively involved in the design and protocol writing of valdecoxib protocol and gave local clinical input for the other two protocols; b) Completed 3 local phase IV trials (atorvastatin, ziprasidone and omesartan), Two manuscripts (the first two products) were submitted to Journal for publication. I was the author of ziprasidone trial, and responsible for interpretation of study results for these three studies. c) Completed 1 Phase II trial (lasofoxifene, JADE) for Japanese development. d) In 2007, the clinical team was carrying out 44 on-going Phase II - Phase IV clinical projects, including sunitinib, pregabalin, PF676, celecoxib, sidanafil for PAH, ziprasidone, asenapine, varenicline, and irinotecan, etc. e) There had been about 55 IIR projects from 2005 to 2007, including disease epidemiology, non-clinical study (in vitro & in vivo), and clinical trials. 4) Established dedicated outcome research team and partnering with Regional CoE and NYHQ to develop OR and access objectives for Taiwan and implement pertinent initiatives. (Vfend project granted by ISPOR Poster Finalist Award, and Best Practice Award by WORF)

Janssen- Cilag, Johnson & Johnson - Taiwan **April – November 2004**

Senior Medical and CNS Marketing Director

Reported to Managing Director, Taiwan, and be a member of Management Board, Janssen-Cilag, Taiwan. Responsible for medical affairs operations with 1 direct report (Manager), as well as head of marketing and sales operations of CNS franchise, with 2 direct reports (Group Product Managers), 3-4 dotted line reports (Junior Managers and Associate Sales Director in CNS Products),
Additionally responsible for the regulatory affairs and clinical research teams.

Key Achievements: 1) Launch Consta (risperidone) injection with premium reimbursement price, 2) Migraine indication for Topamax (topiramide) and launched this indication with reimbursement, 3) Achieved optimal reimbursement price and launch Concerta (methylphenidate Oros).

Pfizer, Taiwan, JAALA, PGP **March 2003 – March 2004**

Associate Medical Director
Reported to Medical Director, Taiwan. Responsibilities for safety and medical information, 1 direct report, providing medical support to products in the therapeutic areas of CNS, COX-2 portfolio, arthritis and pain, oncology, and ophthalmology, involving clinical research (strategy, protocol design and implementation), local NDA registration and pre-launch as well as post-launch medical marketing.

Pharmacia Corporation (acquired by Pfizer in 2003), Taiwan/Hong Kong **Jul 2001 – Mar 2003**

Clinical Sciences Adviser, **Taiwan & Hong Kong, Asia Pacific Region, Global Clinical Science, Pharmacia**
Reported to Asia Pacific Regional Director of Clinical Sciences and General Manager of Pharmacia, Taiwan and Pharmacia, Hong Kong. Responsibilities include executive member of country management, medical marketing strategy and implementation, and providing medical support to marketing and sales elements. Responsible for:

- **Key Opinion Leader Development and Management:** Developing and maintaining personal professional relationships with KOLs and academic centers through conveying complex medical and cutting-edge scientific information and data by delivering lectures or peer-to-peer one-on-one communication to accelerate the acceptance of Pharmacia products within market place and identify further leveraging opportunities for Pharmacia's product line.
- **Advocacy Strategy and Implementation:** Developing advocacy groups and leverage Pharmacia's healthcare initiatives to support country/regional business needs.
- **Medical Marketing Strategy and Implementation:** Developing and implementing unique medical education programs in highly prioritized accounts. Partnering with customers to identify opportunities for development of treatment algorithms and guidelines.
- **Marketing and Sales Support:** Providing clinical input to help marketing elements in strategic planning of business
- **Management:** Participating in strategic planning mechanism at market country level, feedback needs of MC through global clinical sciences system to seek support from region/corporate.
- **Major product coverage:** Corporate global focus including 3 COX-2 portfolio products and Inspra (hypertension and heart failure), pre-marketing and 18 months after launch.

Achievements:

- Help marketing and sales teams achieved 50% excess of annual sales target of Celebrex (celecoxib) by impacting 3000 medical doctors, pharmacists and other medical professionals through establishing medical marketing function and new strategy and delivering 40 lectures and more than 100 one-on-one communications in 18 months in Taiwan.
- Enhanced field force productivity and effectiveness of relationship development between sales team and key hospitals and accounts through establishing professional contacts with "impossible to meet" physicians (eg. Reimbursement review committee members, hospital superintendents, department heads and members of P & T committee and "very busy" senior physicians in Taiwan) making subsequent visits by raps easier and more productive.

- Succeed to organize and personally deliver 4 lectures at grand rounds at medical centers in Taiwan (Challenging task in Taiwan due to my "commercial" connections with Pharmacia)
- Delivered 5 lectures in various Thailand Royal Colleges and in grand rounds at Orthopedic Department at the University of Chiang Mai University.

National Cheng Kung University and University Hospital, Taiwan 1988 – 2007

Clinical Research Centre for New Drug Development 2000-2001
Director

- Completed planning and established research ward, laboratory for pharmacokinetic study, and related facilities.
- Recruited, organized and trained research nurse team.
- Established and upgraded all standard of operation procedures.
- Administration, including fund and budget application and implementation.

Academic and Clinical Department of Psychiatry 1994-2001
Director

- Accountability to the department affairs within the university and university hospital.
- Governing and coordinating the administration of the department, including people management, administration routines, strategy and implementation of the development plans for the department and budgeting.
- Responsible for a department of 43 professionals including 12 medical doctors, 18 psychiatric nurses, and 13 other allied professionals.

Achievements:

- Established 4 research laboratories, including Clinical Psychopathology and Psychometrics, Neuroimaging, Psychoneurophysiology, and Psychopharmacology and Molecular Psychiatry.
- Enhanced research quality and quantity in the department.

Professorship & Consultant Psychiatrist 1988 – 2007

Honorary Associate Professor, Department of Psychiatry, College of Medicine 2001 – 2007
Associate Professor, Department of Psychiatry, College of Medicine 1995 – 2001
Lecturer, Department of Psychiatry, College of Medicine 1988 – 1994

Responsibilities included:

- Research in general psychiatry, anxiety, depression, schizophrenia, psychiatric epidemiology, psychopharmacology, psychosomatic medicine, and social medicine.
- Education, teaching and training for medical students, psychiatry residents and other allied professionals.
- Clinical service: In-patient, out-patient, and consultation.

Achievements:

- Personally or with collaboration, completed approximately 20 research projects in anxiety, depression, breast cancer, schizophrenia, headache, migraine, suicide and geriatrics.
- Involved in 4 clinical trials for antidepressant and antipsychotics.
- Published 35 original research articles in peer review journals, including British Medical Journal, British Journal of Psychiatry, Psychiatric Research, Journal of Psychosomatic Research and Comprehensive Psychiatry.
- Supervised 4 master and 1 PhD level postgraduate students in Clinical Pharmacy and Behavioral Medicine.
- Supervised approximately 20 psychiatric residents completing their psychiatric specialist training programs.
- "Best Teacher of the Year" in 1999 and 2000

Member & Executive Secretary, Ethical Committee for Human Research 1994 – 2001
Achievements:

- Executive Secretary to the Ethical Committee for Human Research of the University and University Hospital from 2000 to 2001.
- Upgrade quality and process of review according to ICH guideline.
- Reforming the infrastructure related to governance of human research carried out in the hospital.
- Chairman of Join Institution Review Board (JIRB) in Taiwan in 2001

National Taiwan University Hospital, Department of Psychiatry, Taiwan 1984 – 1988
Chief Resident 1987-1988
Resident 1984-1987

Responsibilities included (Chief Resident):

- Coordinator, curriculum and schedule of resident training program.
- Coordinator, curriculum and schedule of medical student training program.
- Help department head with internal administrative affairs.
- 35 psychiatry trainees (residents) in the program

Achievements:

- Board Certified Psychiatry Specialist, Registration No. 0154.
- Completed one research study resulting in personal first academic publication.

PROFESSIONAL APPOINTMENTS:

2014 – Present	Clinical Group Head, GIPB, Pfizer Inc
2013	Asia Clinical Development Head, EMBU, Pfizer Inc
2011 – 2012	Regional Clinical Development Director, PCBU, Pfizer Inc
2009 - 2011	Director, Clinical Sciences, PCBU, Pfizer Inc
2007 – 2009	Associate Director, CNS Clinical Development, Pfizer Global Research & Development, Pfizer Inc
2004 Nov – 2007	Medical Director, Pfizer Taiwan
2004 Apr - Oct	Senior Medical and CNS Marketing Director, Janssen-Cilag, Taiwan, Johnson and Johnson
2003 - 2004	Associate Medical Director, Taiwan, JAALA, Pfizer Global Pharmaceuticals
2001- 2003	Clinical Sciences Adviser, Taiwan & Hong Kong, Asia Pacific Region, Global Clinical Science Pharmacia (From 17 April, 2003, acquired by Pfizer)
1994-2001	Director, Department of Psychiatry, National Cheng Kung University Hospital, Tainan, Taiwan (resigned because of joining Pharmacia)
1995-2001	Director, Department of Psychiatry, College of Medicine, National Cheng Kung University, Tainan, Taiwan (resigned because of joining Pharmacia)
2000-2001	Director, Clinical Research Centre, National Cheng Kung University Hospital, Tainan, Taiwan (resigned because of joining Pharmacia)
Mar-June 2001	Chairman, Joint Institution Review Board, Taiwan (leaving the position because of joining Pharmacia Corporation)

Nathan Chen, 123456789nc@gmail.com

2000-2001	Member, Joint Institution Review Board, Taiwan
1996-2001	Member of Ethical Committee of Research on Human Subject, National Cheng Kung University Hospital, Tainan, Taiwan
2000-2001	Secretary General, Ethical Committee of Research on Human Subject, National Cheng Kung University Hospital, Tainan, Taiwan
1994-1995	Acting Director, Department of Psychiatry, National Cheng Kung University Medical College & University Hospital, Tainan, Taiwan
1988 – 2001	Consultant, Department of Psychiatry, National Cheng Kung University Hospital, Tainan, Taiwan
1990-1994	Research Associate, Department of Psychological Medicine, Institute of Psychiatry, London, United Kingdom
1987-1988	Chief Resident, Department of Psychiatry, National Taiwan University Hospital, Taipei, Taiwan
1984-1987	Resident in Psychiatry, National Taiwan University Hospital, Taipei, Taiwan

EDUCATION:

MD in Medicine, 1984
China Medical College, Taiwan

PhD in Psychiatry and Social Medicine, 1994
King's College London & Institute of Psychiatry,
University of London, United Kingdom

MBA in International Business Administration & Management, 2007
University of South Australia, Australia

MSc in Pharmaceutical Medicine, 2007
Hibernia College, Ireland

CERTIFICATES:

Psychiatric Specialist, Taiwan, 1987
No. of Certificate: 0154

Supreme Examination for Medical Doctor, 1985
No. Of Certificate: 74-390

Medical Doctor, Taiwan, 1985
No. Of Certificate: 012916

National Associate Professor Certificate number: 22570

ACADEMIC APPOINTMENTS:

2001-2007	Honorary Associate Professor in Psychiatry, College of Medicine, National Cheng Kung University, Tainan, Taiwan
1995-2001	Associate Professor in Psychiatry, College of Medicine, National Cheng Kung University, Tainan, Taiwan
1988-1995	Lecturer in Psychiatry, National Cheng Kung University Medical College, Tainan, Taiwan

OTHER APPOINTMENTS:

2011	Co-chair, Biomarker in Schizophrenia working group, ISCTM
2005 - 2007	IND taskforce leader, International Research-based Pharmaceutical Manufacturer Association (IRPMA), Taiwan
2005 - 2007	Member, Code of Practice, International Research-based Pharmaceutical Manufacturer Association (IRPMA), Taiwan
2002 – 2005	Member of Core Study Group, National Survey on Mental Disorder
1994-1995	Organizing Committee Member, Division of Mental Health and Drug Abuse, National Health Research Institute, Republic of China
1995-1997	Member of the Board of Director, Society of Psychiatry, R.O.C. (Taiwan)
1998–2001	Member of the Board of director, Society of Psychiatry, R.O.C. (Taiwan)
1998-2001	Member of Editor Board, Chinese Journal of Mental Health
1999	Associate Editor, Taiwanese Journal of Psychiatry

MEMBERSHIPS:

1985	Member of the Society of Psychiatry, R.O.C. (Taiwan)
1994	Member of New York Academy of Sciences, New York, U. S. A.
1995	Member of National Geographic Society, U. S. A.
1995	Fellow of Pacific Rim College of Psychiatrist
1996	International Member of American Psychiatry Association, U.S.A.
1998	Member of East Asian Academy of Cultural Psychiatry
2000	Member of Royal College of Psychiatrist, UK
2009	Member of The International Society for CNS Clinical Trial Methodology

HONOURS & AWARDS:

1987	The Tsai Se-Jim Memorial Award of the Society of Psychiatry, R.O.C. for the distinguished research paper of the year
1990	Excellent Research Award, National Science Council, R.O.C.
1990-1993	Three-year PhD Research Scholarship for University/College Faculty, Ministry of Education, R.O.C.

JOURNAL REFEREEING:

Achieve of General Psychiatry
American Journal of Epidemiology
Taiwanese Journal of Psychiatry (previously named Chinese Psychiatry),
Formosan Journal of Mental Health (previously named Chinese Journal of Mental Health)
Chinese Journal of Public Health (Taipei)
Formosan Journal of Medicine

RESEARCH PROJECTS EXPERIENCE:

Serotonin transporter gene polymorphism and pathogenesis of depression. National Science Council, NSC89-2314-B-006-045.

Correlation of D2 receptor binding activity and personality traits with [^{123}I]-IBZM SPECT. National Council of Atomic Energy. NSC-89-NU-7-006-002 (N4I09)

Cytokines and depression pathogenesis. NSC89-2314-B-006-045

Quality of life and economic benefit between schizophrenics with haloperidol and risperdal. Jassen-Cilag Pharmaceutical, Taiwan

A double-blind, randommized, fluoxetine-controlled, group-comparative study, comparing the tolerability and efficacy of six weeks treatment with Org 3770 and fluoxetine in depressed patients. Organon Taiwan Ltd

Open-label olanzepine in treatment-refractory schizophrenia. Eli Lilly and Company

PNU-101387G double-blind, randomized, placebo- and Olanzapine-controlled, dose-finding study in treatment of psychotic disorders. Pharmacia & Upjohn Taiwan Ltd

Life adversity and plasma corticosteroids. National Science Council, Taiwan. NSC-88-2314-B-006-193

Adverse life events and glycaemic control (III). National Science Council, Taiwan. NSC-87-2314-B-006-020.

Neuroticism, type A behaviour and coping strategies in the onset of non-insulin dependent diabetes mellitus – a case-control study. National Science Council, Taiwan. NSA-87-2314-B-006-022.

Taiwan Old Age Depression Study (TOADS). National Research Institute of Health, Taiwan. D01-86IX-MD-501P.

Adverse life events and glycaemic control (II). National Science Council, Taiwan. NSC-86-2314-B-006-093.

Adverse life events and glycaemic control (I). National Science Council, Taiwan. NSC-85-2331-B-006-043.

A comparative study on the correlation between the psychopathology and handedness of the schizophrenics. National Cheng Kung University Hospital, Taiwan. NCKUHRF-84-059.

One-year follow-up study on patients with headache in the neuropsychiatric outpatient clinics: Psychosocial factors and prognosis. National Science Council, Taiwan. NSC-79-0301-H-0060-4._

PUBLICATIONS:
Referred Papers:

1. CHEN K.C., LEE I.H., YEH T.L., CHIU N.T., CHEN P.S., YANG Y.K., LU R.B., CHEN C.C. (2012) Schizotypy trait and striatal dopamine receptors in healthy volunteers., *Psychiatry Research: Neuroimaging*, 201; 218-221

2. BOLLU V., BUSHMANKIN A.G., CAPPELLEN J.C., CHEN C.C., FELTNER D. and WITTCHEN H. (2010) Pregabalin reduces sleep disturbance in patients with generalized anxiety disorder via both direct and indirect mechanisms. *European Journal of Psychiatry*; 24; 18-27

3. LEE I.H, CHEN C.C.; YEH T.L. ; CHEN K.C.; LEE C.K.; CHEN P.S.; YANG Y.K.; LU R.B., (2010) A community mental health survey and relief program in Taiwan after the great earthquake – implementation, clinical observation and evaluation. *Stress and Health;26* 269-279

4. FARAONE S.V., HWU H.G., LIU C.M., CHEN W.J., TSUANG M.M., LIU S.K., SHIEH M.H.,

HWANG T.J., OUYANG W.C., CHEN C.Y., CHEN C.C., LIN J.J., CHOU F.H.C., CHUEH C.M., LIU W.M., HALL M.H., SU J., VAN EERDEWEGH P., and TSUANG M.T. (2006) Genome Scan of Han Chinese Families from Taiwan: Confirmation of Linkage to 10q22.3. *American Journal of Psychiatry*; 163; 1760-1766.

5. TSAO C.W., LIN Y.S., CHEN C.C., BAI C.H., WU S.R. (2006) Cytokines and serotonin transporter in patients with major depression. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 30; 899-905
6. LEE I.H., CHEN C.C., YANG Y.K., YEH T.L., CHEN P.S., ChIU N.Y. (2005) Correlation between striatal dopamine D2 receptor density and neuroticism in community volunteers. *Psychiatry Research: Neuroimaging*, 138: 259-264
7. HWU HG, FARAONE SV, LIU CM, CHEN WJ, LIU SK, SHIEH MH, HWANG TJ, TSUANG MM, OU YANG WC, CHEN CY, CHEN CC, LIN JJ, CHOU FH, CHUEH CM, LIU WM, HALL MH, TSUANG MT. (2005) Taiwan schizophrenia linkage study: the field study. *American Journal of Medical Genetics B Neuropsychiatric Genetics.* April 5;134(1): 30-6.
8. CHEN PS, YANG YK, LIAO YC, LEE YD, YEH TL, CHEN CC. (2004) The psychological well-being and associated factors of caregivers of outpatients with schizophrenia in Taiwan. *Psychiatry and Clinical Neuroscience.* 58(6): 600-5
9. YEH T.L., HUANG C.L., YANG Y.K., LEE Y.D., CHEN C.C., CHEN P.S. (2004) The adjustment to illness in patients with generalized anxiety disorder is poorer than that in patients with end-stage renal disease. *Journal of Psychosomatic Research*, 57: 165-170
10. CHEN PS, CHEN SJ, YANG YK, YEH TL, CHEN CC, Lo HY (2003) Asperger,s disorder: A case report of repeated stealing and the collecting behaviours of an adolescent patient. Acta Psychiatrica Scandinavica 2003:107:73-76
11. CHO CY, HWANG IS, CHEN CC. (2003) The association between psychological distress and musculoskeletal symptoms experienced by Chinese high school students. *Journal of Orthopedics and Sports Physical Therapy*, 33(6): 344-53.
12. HONG C.J., HU W.H., CHEN C.C., HSIAO C.C., TSAI S.J., RUWE F.J. (2003) A double-blind, randomized, group-comparative study of the tolerability and efficacy of 6 weeks' treatment with mirtazapine or fluoxetine in depressed Chinese patients. Journal of Clinical Psychiatry, 64; 921-926.
13. YANG Y.K., CHIU N.T., LEE L.C., CHEN C.C., LEE I.H., YEH T.L. (2003) The association cognitive performance and between striatal dopamine binding is higher in timing and motor tasks in schizophrenics. Psychiatry Research- Neuroimaging, 123: 37-48
14. YANG Y.K., CHIU N.T., YEH T.L., CHEN C.C. (2003) Correlation between fine motor activity and striatal dopamine D_2 receptor density in patients with schizophrenia and healthy controls. Psychiatry Research-Neuroimaging, 123:191-197
15. LIAO Y.C., YANG Y.K., CHEN P.S., LEE I.H., LEE Y.D., YEH T.L., CHEN C.C. (2003) The comparison of extrapyramidal side effects, cognitive function and economic cost in halperidol-treated and risperidone-treated in outpatients with chronic schizophrenia —— A naturalistic study. Taiwanese Journal of Psychiatry, 17:294-301
16. YANG Y.K., YEH T.L., CHEN C.C., LEE C.K., LEE I.H., LEE L.C., KEITH J.J. (2003) Psychiatric Morbidity and post-traumatic symptoms among earthquake victims in primary care clinics. General Hospital Psychiatry, 25; 253-261.
17. CHEN P.S., CHEN S.J., YANG Y.K., YEH T.L., CHEN C.C., LO H.Y. (2003) Asperger's disorder: A case report of repeated stealing and the collecting behavior of an adolescent patient. Acta Psychiatrica Scandinavica, 170:73-76.
18. YANG Y.K., CHEN C.C., LEE I.H., CHOU Y.H., CHIU N.T., KEITH J.J., TSAI T.T., YEH T.L. (2003) The Association between regional cerebral blood flow and eye-tracking performance and

the Wisconsin Card Sorting Test in schizophrenics: A single photon emission computed tomography study. Psychiatry Research-Neuroimaging, 123: 37-48.

19. YANG Y.K., CHIU N.T., YEH T.L., CHEN C.C., LEE I.H., LO H.Y. (2002) The effect of antipsychotics on extrapyramidal syndrome and dopamine receptors in patients with schizophrenia. Taiwanese Journal of Psychiatry, 16:33-41.

20. LO H.Y., YANG Y.K., CHEN C.C., YEH T.L., LEE I.H., LEE Y.D., CHOU Y.H. (2002) Clinical characteristics of drug abusers with higher relapse tendency in a detention center. Taiwanese Journal of Psychiatry, 16: 1-6.

21. YANG Y.K., CHOW Y.H., CHIU N.T., TSAI T.T., LUO J.M., YEH T.L., CHEN C.C. (2002) Regional cerebral flow, cognitive function and deficit syndrome in schizophrenics with different eye tracking performance. Taiwanese J of Psychiatry, 16:105-16.

13. CHEN W.J., CHEN H.M., CHEN C.C., CHEN C.C., YU W.Y., CHENG A.T.A. (2002) Clonoger's Tridimensional Personality Questionnaire: psychometric properties and construct validity in Taiwanese adults. Comprehensive Psychiatry, 43: 158-166

14. LEE IH, YANG YK, LEE YD, CHOU YH, THE TL, CHEN CC. (2001) Gender differences in the clinical characteristics of drug abusers at a detention center. Taiwanese Journal of Psychiatry, 15: 106-16.

15. WU JM, CHEN CC, YANG YK,YEH TL. (2001) Pilot study of muscle relaxation and thermal biofeedback training group for college students. Chinese Group Psychotherapy, 7: 4-13.

16. CHEN C.C., YEH T.L., YANG Y.K., CHEN H.T., LEE I.H., FU L.S., YEH T.Y., HSU H.C., TSAI W.L., CHENG S.H., CHEN L.Y., SI Y.C. (2001) Psychiatric morbidity and post-traumatic symptoms among survivors in the early stage following the 1999 earthquake in Taiwan. Psychiatric Research, 106: 13-22

17. CHEN C.C., WU J.S., LU F.H., CHANG C.J. (2001) Serum lipids concentration and psychological distress. Psychiatry Research, 102: 153-162.

18. LI T.C., LEE Y.D., LEE Y.Y., CHEN C.C., CHI C.H. (2001) Validation of the Chinese-version MPSS-R for occupational stress among emergency nurses. Journal of Psychosomatic Research 51: 379 – 385.

19. CHEN C.C. (2001) Pathophysiology of Major Depression - a review. Taiwanese Journal of Psychiatry, 15: 3-14.

20. CHONG M.Y., CHEN C.C., TSANG H.Y., YEH T.L., CHEN C.S., LEE I.H., TANG T.C., LO H.Y. (2001) A community study of old age depression in Taiwan: Prevalence, life events and sociodemographic correlates. British Journal of Psychiatry, 178: 29-35

21. CHENG A.T.A., CHEN T.S.S., CHEN C.C., JENKINS R. (2000) Psychosocial and psychiatric risk factors of suicide: A case-control psychological autopsy study. British Journal of Psychiatry, 177: 360-365.

22. CHEN C.C., YANG Y.K., YEH T.L., LEE C.K., SHIH Y.S., KO I.W., WONG D.W. (2001) Risk factors associated with post-disaster suicide ideation and post-traumatic syndrome following an earthquake in Taiwan. Submitted to British Medical Journal.

23. Chen C.C., Tsang H.Y., Yeh T.L., Chong M.Y., Lee I.H., Lo H.Y., Chen T.S., Tang T.C. (2001) Social support, life adversity and old age depression in Taiwan. Psychological Medicine, (reviewed)

24. Chen H.H., Chen C.C., Yeh T.L., Lee C.T., Yu L. (2001) Neuroticism as a factor of development and maintenance of psychiatric morbidity: A longitudinal study. Psychological Medicine,

(reviewed)

25. CHEN C.C., WU J.S., LEE I. H., YEH T.L., CHANG C.J. (2001) Life adversity and plasma glucocorticoids. Psychiatry Research, (reviewed) (NSC85-2331-B-006-043)

26. YEH T.L., YEH S.J., LO C.M., CHEN C.C. (2001) Comorbidity of minor psychiatric disorders and postural tachycardia syndrome (POTS). Journal of Psychosomatic Research, (Revised)

27. YANG Y.K., YEH T.L., CHEN C.C. (1999) Post-traumatic disorder: The Yu-Chyr town experience from a severe earthquake in Taiwan. The Journal of Nursing, 46: 20-29.

28. YANG Y.K., SHIEH H.H., WU C.C., CHEN C.C. (1999) Help seeking behaviors in relatives of schizophrenics in Taiwan. General Hospital Psychiatry 21: 303-309.

29. HUANG J.L., YANG Y.K., CHEN I., CHEN C.C. (1999) Double blind trials of buspirone, lorazepam and diazepam in the treatment of generalized anxiety disorder. Taiwanese Journal of Psychiatry 13: 150-160.

30. CHOU Y.H., YANG Y.K., HUANG C.L., TSAI T.T., CHEN C.C. (1998) Correlates of eye tracking dysfunction and psychopathology in chronic schizophrenic outpatients. Taiwanese Journal of Psychiatry 12:309-319.

31. TSUI S.C., YANG Y.K., SHIEH S.K., WU C.C., CHEN C.C. (1998) Comparison of family burden and needs of home care service between schizophrenic and bipolar disorder patients. Taiwanese Journal of Psychiatry 12:188-193.

32. LEE Y.D., CHI C.H., LI C.Y., CHANG I., CHEN C.C. (1998) Reliability of HDRS and HARS telepsychiatric assessment of anxiety and depression. Taiwanese Journal of Psychiatry 12:236-242.

33. FANG L.H., CHEN G.T., CHEN C.C. (1998) The treatment of depression: A review. Formosan Journal of Medicine 2:456-463.

34. LEE C.S., CHEN C.C., YEH T.L., YANG Y.K., LEE Y.D., WU J.S., LU F.H. (1998) Neuroticism and coping strategies in relation to mental health. Taiwanese Journal of Psychiatry 12:110-119

35. LEE C.S., CHEN C.C., LEE M.B. (1997) Biopsychosocial aspects of stress coping: A review. Taiwanese Journal of Psychiatry 11:105-120.

36. LEE Y.D., WU J.S., CHANG C.J. CHEN C.C. (1996) Differences in psychological distress between males and females attending a general health examination program. Chinese Psychiatry 10:334-345.

37. CHEN C.C., DAVID A., THOMPSON K., SMITH C., LEA S., FAHY T. (1996) Coping strategies and psychiatric morbidity in women attending breast assessment clinics. Journal of Psychosomatic Research 40:265-270.

38. CHEN C.C. (1996) Neurotic and psychosomatic disorders: A review. Student Counseling 46:62-67. (in Chinese)

39. YANG Y.K., SHIH Y.C., YEH T.L., CHEN C.C. (1996) Early Sign Scale in predicting relapse of schizophrenic patients. Chinese Psychiatry 10:24-5.

40. CHEN C.C., DAVID A.S., NUNNERLEY H., DAWSON J.L., BERRY H., DOBBS J., FAHY T. (1995) Adverse life events and breast cancer: case-control study. British Medical Journal 311:1527-1530.

41. CHEN C.C., DAVID A.S., THOMPSON K., SMITH C., LEA S., FAHY T. (1993) Psychiatric morbidity and coping strategies in breast assessment clinics. The Breast 2:200-201.

42. CHEN C.C., FAHY T. (1992) Life events and cancer prognosis. British Medical Journal 304:1632.[letter].

43. CHEN Y.C., HSU C.C., SOONG W.T., KO H.C., CHEN C.C., YEH T.L., LIN S.C., WEN M.C., SU M.J. (1989) A six-year follow-up study of intellectual and behavioral development of yu-cheng children: Findings of the third field work. Chinese Psychiatry 3:89-99.

44. CHEN C.C., HSU C.C., YEH T.L., LIN S.C., DUANN Y.H. (1988) A six-year follow-up study of intellectual and behavioral development of yu-cheng children: Cross-sectional findings of the second field work study. Chinese Psychiatry 2:257-266.

45. YEH T.L., HSU C.C., CHEN C.C., DUANN Y.H., LIN S.C., WEN M.C., SU M.J. (1988) A six-year follow-up study of intellectual and behavioral development of yu-cheng children: Findings of the second year of field work. Chinese Psychiatry 2:172-185.

46. HSU C.C., CHEN C.C., SOONG W.T., TSENG C.C., SUE S.J., LIU C.Y., LIN S.C., CHANG S.H., LIAO S.L. (1988) A six-year follow-up study of intellectual and behavioral development of yu-cheng children: Cross-sectional findings of the first field work study. Chinese Psychiatry 2:27-40.

47. HSU C.C., SOONG W.T., CHANG S.H., CHEN C.C., SUE S.J., CHIU G.S. (1987) Correlates of reading achievement in Chinese: Prevalence rate of the reading disabled school children. Chinese Psychiatry 1:189-197.

48. CHEN C.C., LEE M.B., RIN H. (1986) A clinical comparative study of hospitalised borderline and hebephrenic schizophrenics. Bulletin of Chinese Society of Neurology and Psychiatry 12:130-140.

Conference Papers:

1. CHEN C.C., YEH T.L., LEE I.H., CHANG C.J., WU J.S. (1998) Correlation study on life adversity and plasma glucocorticoids. Presented in the XVI congress of the World Association for Social Psychiatry, Vancouver, B.C., Canada, August 16-21.
2. CHANG W.T., CHEN C.C. (1998) The effect of ginseng component ginsenoside RB1 on striatal dopaminergic system of the rat. Presented in the XVI congress of the World Association for Social Psychiatry, Vancouver, B.C., Canada, August 16-21.
3. YANG Y.K., TSUI S.C., SHIEH S.H., WU C.C., CHEN C.C. (1998) Comparison of family burden and needs for home care service between schizophrenia and bipolar disorder in Taiwan. Presented in the XVI congress of the World Association for Social Psychiatry, Vancouver, B.C., Canada, August 16-21.
4. CHONG M.Y., LIN K.C., TSANG H.Y., CHEN C.S., CHEN C.C. (1998) Handicap of elderly people in the community with psychiatric disorders. Presented in the XVI congress of the World Association for Social Psychiatry, Vancouver, B.C., Canada, August 16-21.
5. DOONG J.H., LEE Y.D., CHEN C.C. (1998) The reliability and validity of short-form McGill pain questionnaire (Taiwanese version). Presented in the 37th annual meeting of the Society of Psychiatry, R.O.C. (Taiwan) Tainan, Taiwan, November 1998.

6. CHOU Y.H., LEE I.H., YANG Y.K., YEH T.L., CHEN C.C. (1998) Barnes akathisia rating scale (BAS) – Development and reliability study of a Taiwnaese version. Presented in the 37th annual meeting of the Society of Psychiatry, R.O.C. (Taiwan) Tainan, Taiwan, November 1998.
7. HUANG C.L., YANG Y.K., LEE Y.D., YEH T.L., CHEN C.C. (1998) Comparison of the adjustment between patients with generalised anxiety disorder and chronic renal disease. Presented in the 37th annual meeting of the Society of Psychiatry, R.O.C. (Taiwan) Tainan, Taiwan, November.
8. YANG Y.K., CHOU Y.H., CHIU N.T., TSAI T.T., LUO C.M. YEH T.L., CHEN C.C. (1998) Regional cerebral flow, cognitive function and deficit syndrome in schizophrenics with different eye tracking performance. Presented in the 37th annual meeting of the Society of Psychiatry, R.O.C. (Taiwan) Tainan, Taiwan, November.
9. LEE I.H., CHEN C.C., YEH T.L., LO E.H.Y., CHANG C.J., WU J.S. (1997) Correlation study on

adverse life events and plasma stress hormones. Presented in the 36th annual meeting of the Society of Psychiatry, R.O.C., Taiwan, Taipei, Taiwan, November 15-16.

10. LO E.H.Y., CHEN C.C., YEH T.L., LEE I.H., CHANG C.J., WU J.S. (1997) Development and validation of Taiwanese Life Events and Difficulties Schedule. Presented in the 36th annual meeting of the Society of Psychiatry, R.O.C., Taiwan, Taipei, Taiwan, November 15-16.
11. CHEN I.T., LEE Y.D., CHEN C.C., TSAI J.J. (1997) Reliability and validity of the Chinese Quality of Life Index used in patients with the epileptic disease. Presented in the 36th annual meeting of the Society of Psychiatry, R.O.C., Taiwan, Taipei, Taiwan, November 15-16.
12. DOONG J.H., LEE Y.D., CHEN C.C., LEE P.C., HUANG J.J., SUNG J.M., LAN R.R., RUAN M. K. (1997) Comparison of the quality of life between kidney transplantation and dialytic therapy. Presented in the 36th annual meeting of the Society of Psychiatry, R.O.C., Taiwan, Taipei, Taiwan, November 15-16.
13. CHEN C.C. (1997) Neuropsychiatric changes in older women. Invited speech in the 3rd annual meeting of the Taiwan Menopause Society, Tainan, Taiwan. March 1997.
14. CHEN C.C., LEE Y.D., WU J.S., CHANG C.J. (1996) Psychological health in attenders of a general health screening. Presented in the VII Congress of International Federation of Psychiatric Epidemiology. Santiago de Compostela, Spain. NSC-86-0501-I-006-059-A1
15. LEE C.S., CHANG J.C., TSAO C.J., CHEN C.C. (1996) Hospice care for cancer patients: A psychosomatic model in southern Taiwan. Psycho-Oncology 5 (supplement):56.
16. CHANG J.C., LEE C.S., YANG Y.J., CHEN C.C. (1996) The stress variance, quality of life and health status among hospice nurses in Taiwan. Psycho-Oncology 5 (supplement):39
17. CHEN C.C., FAHY T., HUMPHREY S., DAVID A.S. (1995) Adverse life events and grade of malignancy on the diagnosis of breast cancer. Proceeding of the 2nd International Congress of Psycho-Oncology. Kobe, Japan. p183.
18. YANG Y.K., SHIH Y.C., YEH T.L., CHEN C.C. (1994) A preliminary investigation of early prediction for relapse in schizophrenic patient. Proceeding of the International Conference on Relapse of Schizophrenia. Kaohsiung, Taiwan, p53.
19. CHEN C.C., DAVID A.S., THOMPSON K., SMITH C., LEA S. (1993) Coping strategies and psychiatric morbidity in breast assessment clinics. Proceeding of the 12th World Congress of Psychosomatic Medicine. Berne, Switzerland. September, 1993.
20. LEE E.J., YEH T.L., LIAO I.C., CHEN C.C., HSU C.C. (1989) A review of attempted suicide case encountered at the National Cheng Kung University Hospital. Presented in the 1989 annual meeting of the Society of Psychiatry, R.O.C. (Taiwan) September, 1989.
21. CHEN C.C. (1989) Common psychosomatic disorders in general psychiatric practice: A review. Presented in the symposium of minor mental disorders. The Society of Psychiatry, R.O.C. (Taiwan). June 1989.
22. CHEN C.C., LIU C.Y., SOONG W.T., CHIU Y.N., SU S.J. (1986) An experimental model: Simultaneous child social skills training group - Part (II): Preliminary report of parenting skills training groups. Proceeding of 1986 annual meeting of the Society of Neurology and Psychiatry. Taipei, Taiwan. November 1986.
23. CHIU Y.N., SU S.J., SOONG W.T., CHEN C.C., LIU C.Y. (1986) An experimental model: Simultaneous child social skills training group - Part (I): Preliminary report of child social skills training groups. Proceeding of 1986 annual meeting of the Society of Neurology and Psychiatry. Taipei, Taiwan. November 1986.

Other:

1. CHONG M.Y., TSANG H.Y., CHEN C.C. (1998) Taiwan Old Age Depression Study. Report to the National Research Institute of Health. D01-86IX-MD-501P.
2. CHEN C.C. (1998) Adverse life events and glycaemic control. Report to the National Science Council. NSC-87-2314-B-006-020.
3. CHEN C.C., LEE Y.D. (1998) Neuroticism, type A behaviour and coping strategies in the onset of non-insulin dependent diabetes mellitus – a case-control study Report to the National Science Council. NSA-87-2314-B-006-022.
4. CHEN C.C. (1997) Adverse life events and glycaemic control. Report to the National Science Council. NSC-86-2314-B-006-093.
5. CHEN C.C., YEH T.L. (1997) Manual for life events and difficulties interview and rating. Tainan, Long-Mong Press Ltd. (in Chinese)

6. CHEN C.C. (1996) Adverse life events and glycaemic control. Report to the National Science Council. NSC-85-2331-B-006-043.
7. CHEN C.C., CHEN H.T. (1995) A comparative study on the correlation between the psychopathology and handedness of the schizophrenics. Report to the National Cheng Kung University Hospital. NCKUHRF-84-059.
8. CHEN C.C. (1994) Psychosocial stress, coping and risk of breast cancer. An unpublished PhD thesis, University of London.
9. CHEN C.C., LAI M.L. (1990) Follow-up study on headaches in neuropsychiatric outpatient clinic outcome and psychosocial factors. Research report for grant supported by National Science Council, No. NSC-79-0301-H006-04. Carrying out from Oct. 1989 to Sep. 1990.

Nathan Chen, 123456789nc@gmail.com